Top

Published in:

01-04-2009 | Preclinical Study

Increased epidermal growth factor receptor (EGFR) expression in malignant mammary phyllodes tumors

Authors: Gary M. K. Tse, Philip C. W. Lui, Joaquim S. L. Vong, Kin-Mang Lau, Thomas C. Putti, Rooshdiya Karim, Richard A. Scolyer, C-Soon Lee, Alex M. C. Yu, David C. H. Ng, Agnes K. Y. Tse, Puay-Hoon Tan

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Abstract

Mammary phyllodes tumors are uncommon stromal-epithelial neoplasms, and are divided into benign, borderline malignant and frankly malignant groups on the basis of their histological features. Accumulating evidence shows that epidermal growth factor receptor (EGFR) is involved in the pathogenesis and progression of many malignancies. This study investigated 453 phyllodes tumors (296 benign, 98 borderline, 59 malignant) for EGFR expression using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for gene amplification. The staining was correlated to tumor margin status, degree of malignancy, stromal cellularity, mitotic activity, nuclear pleomorphism and stromal overgrowth. Cases with strong positive IHC staining were selected for FISH. The overall positive rate for EGFR was 16.2% (48/296), 30.6% (30/98) and 56% (33/59) for benign, borderline malignant and frankly malignant phyllodes tumors, respectively. FISH demonstrated egfr gene amplification in 8% of immunohistochemically positive cases. The results of this study provide strong evidence that EGFR overexpression is involved in the pathogenesis of phyllodes tumors, although gene amplification may not be the major underlying mechanism for overexpression.

Reinfuss M, Mituś J, Duda K et al (1996) The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. Cancer 77:910–916PubMedCrossRef

Pietruszka M, Banes L (1978) Cystosarcoma phyllodes: a clinicopathological analysis of 42 cases. Cancer 41:1974–1983PubMedCrossRef

Salvadori B, Cusumano F, Del Bo R et al (1989) Surgical treatment of phyllodes tumors of the breast. Cancer 63:2532–2536PubMedCrossRef

Halverson JD, Hori-Rubaina JM (1974) Cystosarcoma phyllodes of the breast. Am Surg 40:295–301PubMed

Kersting C, Kuijper A, Schmidt H et al (2006) Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression. Lab Invest 86:54–61PubMedCrossRef

Tan PH, Jayabaskar T, Yip G et al (2005) p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors a tissue microarray study. Mod Pathol 18:1527–1534PubMedCrossRef

Niezabitowski A, Lackowska B, Rys J (2001) Prognostic evaluation of proliferative activity and DNA content in the phyllodes tumor of the breast: immunohistochemical and flow cytometric study of 118 cases. Breast Cancer Res Treat 65:77–85PubMedCrossRef

Tse GM, Lui PC, Lee CS et al (2004) Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: a multicenter study of 185 cases. Hum Pathol 35:1053–1057PubMedCrossRef

Tsai WC, Jin JS, Yu JC et al (2006) CD10, actin, and vimentin expression in breast phyllodes tumors correlates with tumor grades of the WHO grading system. Int J Surg Pathol 14:127–131PubMedCrossRef

10.

Tse GM, Putti TC, Kung FY et al (2002) Increased p53 protein expression in malignant mammary phyllodes tumors. Mod Pathol 15:734–740PubMedCrossRef

11.

Perry A, Kunz SN, Fuller CE et al (2002) Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol 61:702–709PubMed

12.

Tan PH, Jayabaskar T, Chuah KL et al (2005) Phyllodes tumors of the breast: the role of pathologic parameters. Am J Clin Pathol 123:529–540PubMedCrossRef

13.

Bencardino K, Manzoni M, Delfanti S et al (2007) Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues. Intern Emerg Med 2(1):3–12PubMedCrossRef

14.

Le Tourneau C, Faivre C, Siu LL (2007) Molecular targeted therapy of head and neck cancer: review and clinical development challenges. Eur J Cancer 43(17):2457–2466PubMedCrossRef

15.

Feakins RM, Wells CA, Young KA (2000) Platelet-derived growth factor expression in phyllodes tumors and fibroadenomas of the breast. Hum Pathol 31:1214–1222PubMedCrossRef

16.

Chan YJ, Chen BF, Chang CL et al (2004) Expression of p53 protein and Ki-67 antigen in phyllodes tumor of the breast. J Chin Med Assoc 67:3–8PubMed

17.

Chen CM, Chen CJ, Chang CL et al (2000) CD34, CD117, and actin expression in phyllodes tumor of the breast. J Surg Res 94:84–91PubMedCrossRef

18.

Tse GM, Putti TC, Lui PC et al (2004) Increased c-kit (CD117) expression in malignant mammary phyllodes tumors. Mod Pathol 17:827–831PubMedCrossRef

19.

Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitnib. N Engl J Med 21:2129–2139CrossRef

20.

Ji H, Zhao X, Yuza Y et al (2006) Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci USA 103:7817–7822PubMedCrossRef

21.

Lee J, Vivanco I, Beroukhim R et al (2006) Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 3(12):e485PubMedCrossRef

22.

Sugawa N, Ekstrand AJ, James CD et al (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87:8602–8606PubMedCrossRef

23.

Steinman S, Wang J, Bourne P et al (2007) Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci 37:127–134PubMed

24.

Yang JL, Hannan MT, Russell PJ et al (2006) Expression of HER1/EGFR protein in human soft tissue sarcomas. Eur J Surg Oncol 32:466–468PubMedCrossRef

25.

Reis-Filho JS, Pinheiro C, Lambros MB et al (2006) EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 209:445–453PubMedCrossRef

26.

Sato O, Wada T, Kawai A et al (2005) Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases. Cancer 103:1881–1890PubMedCrossRef

27.

Suo Z, Nesland JM (2000) Phyllodes tumor of the breast: EGFR family expression and relation to clinicopathlogical features. Ultrastruct Pathol 24:371–381PubMedCrossRef

28.

Wang X, Jones TD, Zhang S et al (2007) Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. Mod Pathol 20:175–182PubMedCrossRef

29.

Kersting C, Tidow N, Schmidt H et al (2004) Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma. Lab Invest 84:582–587PubMedCrossRef

30.

Kersting C, Packeisen J, Leidinger B et al (2006) Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas. J Clin Pathol 59:585–590PubMedCrossRef

31.

Agelopoulos K, Kersting C, Korsching E et al (2007) Egfr amplification specific gene expression in phyllodes tumors of the breast. Cell Oncol 29(6):443–451PubMed

32.

Dobashi Y, Suzuki S, Sugawara H et al (2007) Involvement of epidermal growth factor receptor and downstream molecules in bone and soft tissue tumors. Hum Pathol 38:914–925PubMedCrossRef

33.

Wong SF (2005) Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 27:684–694PubMedCrossRef

34.

Feng FY, Lopez CA, Normolle DP et al (2007) Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo. Clin Cancer Res 13:2512–2518PubMedCrossRef

35.

Perez-Torres M, Guix M, Gonzalez A et al (2006) Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations. J Biol Chem 281:40183–40192PubMedCrossRef

36.

Paez JG, Jänne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500PubMedCrossRef

37.

Smith J (2005) Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Clin Ther 27:1513–1534PubMedCrossRef

Title: Increased epidermal growth factor receptor (EGFR) expression in malignant mammary phyllodes tumors
Authors: Gary M. K. Tse
Philip C. W. Lui
Joaquim S. L. Vong
Kin-Mang Lau
Thomas C. Putti
Rooshdiya Karim
Richard A. Scolyer
C-Soon Lee
Alex M. C. Yu
David C. H. Ng
Agnes K. Y. Tse
Puay-Hoon Tan
Publication date: 01-04-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0030-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Time-varying pattern of recurrence risk for Chinese breast cancer patients

Mutations of the MYH gene do not substantially contribute to the risk of breast cancer

The prognostic and predictive values of circulating HER-2/neu extracellular domain in patients with metastatic breast cancer

Prognostic imaging in neoadjuvant chemotherapy of locally-advanced breast cancer should be cost-effective

Molecular mechanisms of the D327N SHBG protective role on breast cancer development after estrogen exposure

Cost–effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer